Current, new and future treatments of osteoporosis (Q37777053)

23 August 2017

1 reference

title

Current, new and future treatments of osteoporosis (English)

1 reference

23 August 2017

0 references

Mohammad Abdollahi

2

0 references

Bagher Larijani

series ordinal

3

object named as

Bagher Larijani

1 reference

23 August 2017

Pooneh Salari Sharif

1

1 reference

23 August 2017

30 July 2010

1 reference

Rheumatology International

23 August 2017

1 reference

23 August 2017

31

1 reference

23 August 2017

289-300

1 reference

23 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s00296-010-1586-z

23 August 2017

0 references

cites work

Clinical assessment of fracture risk and novel therapeutic strategies to combat osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Controversial effects of non-steroidal anti-inflammatory drugs on bone: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Calcium plus vitamin D supplementation and the risk of fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

A systematic review of persistence and compliance with bisphosphonates for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Bisphosphonate-induced osteopetrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Osteoporosis prevention and therapy: preserving and building strength through bone quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Update of current therapeutic options for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

The correction of BMD measurements for bone strontium content.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Strontium ranelate promotes osteoblastic differentiation and mineralization of murine bone marrow stromal cells: involvement of prostaglandins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Targeting the Wnt signaling pathway to augment bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Control of the SOST bone enhancer by PTH using MEF2 transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Differential turnover of cortical and trabecular bone in transgenic mice overexpressing cathepsin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Expression profiles of mRNAs for osteoblast and osteoclast proteins as indicators of bone loss in mouse immobilization osteopenia model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Proteinases in bone resorption: obvious and less obvious roles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Selective androgen receptor modulators as function promoting therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Cell adhesion molecules: potential therapeutic & diagnostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

The alpha v beta 3 integrin "vitronectin receptor"

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Involvement of alpha(v)beta3 integrins in osteoclast function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

L-carnitine and isovaleryl L-carnitine fumarate positively affect human osteoblast proliferation and differentiation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

L: -carnitine fumarate and isovaleryl-L: -carnitine fumarate accelerate the recovery of bone volume/total volume ratio after experimetally induced osteoporosis in pregnant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Systemic administration of adrenomedullin(27-52) increases bone volume and strength in male mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Expression of adrenomedullin and its receptor during embryogenesis suggests autocrine or paracrine modes of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Amylin fasting plasma levels are decreased in patients with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Adrenomedullin is anti-apoptotic in osteoblasts through CGRP1 receptors and MEK-ERK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

21 January 2018

Growth hormone and bone

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

The skeletal structure of insulin-like growth factor I-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Effects of systemic and local administration of recombinant human IGF-I (rhIGF-I) on de novo bone formation in an aged mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Pharmacological topics of bone metabolism: antiresorptive microbial compounds that inhibit osteoclast differentiation, function, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Prospects for osteoprogenitor stem cells in fracture repair and osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Combination of bone tissue engineering and BMP-2 gene transfection promotes bone healing in osteoporotic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1586-Z

Role of muscle-derived growth factors in bone formation

21 January 2018

1 reference

12 December 2020

Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K

1 reference

12 December 2020

Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice

1 reference

12 December 2020

LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo

1 reference

12 December 2020

Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats

1 reference

12 December 2020

The effect of n-3 fatty acids on bone biomarkers in Iranian postmenopausal osteoporotic women: a randomized clinical trial

1 reference

12 December 2020

Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women

1 reference

12 December 2020

Induction of a program gene expression during osteoblast differentiation with strontium ranelate

1 reference

12 December 2020

Effect of different doses of nasal salmon calcitonin on bone mass

1 reference

12 December 2020

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

1 reference

12 December 2020

Effects of Intermittent Parathyroid Hormone Administration on Bone Mineralization Density in Iliac Crest Biopsies from Patients with Osteoporosis: A Paired Study before and after Treatment

1 reference

12 December 2020

Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats.

1 reference

12 December 2020

Effects of amylin and adrenomedullin on the skeleton

1 reference

12 December 2020

Effect of calcium supplementation on fracture risk: a double-blind randomized controlled trial

1 reference

12 December 2020

Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus

1 reference

12 December 2020

OPG and RANKL mRNA and protein expressions in the primary and secondary metaphyseal trabecular bone of PTH-treated rats are independent of that of SOST

1 reference

12 December 2020

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

12 December 2020

Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.

1 reference

12 December 2020

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women

1 reference

12 December 2020

Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo

1 reference

12 December 2020

Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures?

1 reference

12 December 2020

Parathyroid hormone in the treatment of involutional osteoporosis: back to the future.

1 reference

12 December 2020

Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio

1 reference

12 December 2020

Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)

1 reference

12 December 2020

Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women

1 reference

12 December 2020

Effects of an inhibitor of cathepsin L on bone resorption in thyroparathyroidectomized and ovariectomized rats

1 reference

12 December 2020

A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis.

1 reference

12 December 2020

Strontium ranelate for preventing and treating postmenopausal osteoporosis

1 reference

12 December 2020

The role of cytokines in osteoarthritis pathophysiology

1 reference

12 December 2020

Mechanical stimulation in vivo reduces osteocyte expression of sclerostin

1 reference

12 December 2020

Repair of large bone defects with the use of autologous bone marrow stromal cells

1 reference

12 December 2020

RANKL inhibition: from mice to men (and women).

1 reference

12 December 2020

A potential role for adrenomedullin as a local regulator of bone growth

1 reference

12 December 2020

Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial

1 reference

12 December 2020

Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density

1 reference

12 December 2020

Determination of Oxidative Stress Status and Concentration of TGF-β1 in the Blood and Saliva of Osteoporotic Subjects

1 reference

12 December 2020

A novel carborane analog, BE360, with a carbon-containing polyhedral boron-cluster is a new selective estrogen receptor modulator for bone

1 reference

12 December 2020

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial

1 reference

12 December 2020

10.1007/S00296-010-1586-Z

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20676643